SUPN May 2024 34.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:57AM EDT. Market open.
Loading interactive chart…
- GuruFocus.com
Supernus Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Strategic Shifts and Pipeline ...
Despite Challenges, Company Shows Promising Growth in Key Areas
- Simply Wall St.
Supernus Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.002 (vs US$0.31 in 1Q 2023)
Supernus Pharmaceuticals ( NASDAQ:SUPN ) First Quarter 2024 Results Key Financial Results Revenue: US$143.6m (down 6.6...
- GlobeNewswire
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and conference call on Thursday, May 23, 2024, at 4:30 p.m. ET to review interim data from the open-label Phase IIa study of SPN-817 for treatment-resistant seizures. A live webcast with presentation slides will
© 2024 Yahoo. All rights reserved.